We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

This study has been withdrawn prior to enrollment.
(Due to company decision to focus resources on a larger, controlled study in this patient population.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00446602
First Posted: March 13, 2007
Last Update Posted: September 20, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Ortho Biotech Clinical Affairs, L.L.C.
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: August 2009
  Primary Completion Date: No date given